Myotonic dystrophy type 1 (DM1) is an RNA-mediated disorder caused by a non-coding CTG repeat expansion that, in particular, provokes functional alteration of CUG-binding proteins. As a consequence, several genes with misregulated alternative splicing have been linked to clinical symptoms. In our search for additional molecular mechanisms that would trigger functional defects in DM1, we took advantage of mutant gene-carrying human embryonic stem cell lines to identify differentially expressed genes. Among the different genes found to be misregulated by DM1 mutation, one strongly downregulated gene encodes a transcription factor, ZNF37A. In this paper, we show that this defect in expression, which derives from a loss of RNA stability, is controlled by the RNA-binding protein, CUGBP1, and is associated with impaired myogenesis-a functional defect reminiscent of that observed in DM1. Loss of the ZNF37A protein results in changes in the expression of the subunit a1 of the receptor for the interleukin 13. This suggests that the pathological molecular mechanisms linking ZNF37A and myogenesis may involve the signaling pathway that is known to promote myoblast recruitment during development and regeneration.
INTRODUCTION
Myotonic dystrophy type 1 (DM1), the most common form of adult-onset muscular dystrophy, is caused by an abnormal CTG repeat expansion in the 3 ′ UTR (untranslated region) of the gene encoding a protein kinase (DMPK). This disease has a peculiar molecular basis because most of the clinical symptoms are not directly due to a defect in the function of the mutant DMPK gene (1, 2) . Instead, abnormalities are introduced in the processing of a variety of genes by an indirectly triggered defective activity of proteins involved in mRNA processing; this is the result of the presence of the mutant DMPK RNA in the cell nucleus (3) . The identification of RNA-binding proteins bound to the abnormal CUG repeat expansion indicated an RNA gain-of-function model for DM1. Indeed, a number of changes in tissue-specific patterns of gene alternative splicing have been shown to contribute to the specific symptoms in DM1 patients (3, 4) .
In addition to these mechanisms, or as a secondary consequence of abnormal splicing in a signaling cascade, more recent studies have highlighted the existence of gene expression alterations in DM1 cells. Using differential transcriptomics, we specifically identified 15 genes that exhibited up-or downregulation in cells differentiated from stem cell lines derived from human embryos characterized as carrying the DM1 gene in a preimplantation genetic diagnosis (PGD) procedure (5, 6) . How * To whom correspondence should be addressed. Email: cmartinat@istem.genethon.fr # The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com such changes in gene expression may contribute to the disease phenotype remains to be established. Within this framework, ZNF37A-one of the most severely downregulated genesparticularly attracted our attention because it is a potential transcription factor. Modification of expression of transcription factors has been described in DM1 and may provide a powerful explanation for broad gene expression changes. This has been demonstrated for the abnormal heart Nkx2.5 induction in a DM1 mouse model (7, 8) . These findings also highlight the notion that the requirement for transcription factors in different tissues expressing the mutation may account for the multisystemic nature of DM1.
In the general framework of our search for new pathological mechanisms of DM1, we began with the identification of the expression defect of ZNF37A and subsequently explored its role in the DM1 pathophysiology. Derivatives of human ES cell lines were used in this study because they provide the dual advantage of the production of an unlimited number of cells, as a result of their indefinite capacity for self-renewal, and their ability to differentiate into homogenous cell populations of discrete phenotypes (9) . As a complement to such studies, PGD permits the precise characterization of the genomic defect of the cell lines.
Our study reveals that the altered expression of the Krabdomain, zinc-finger transcriptional repressor factor ZNF37A bears functional consequences in myogenesis. The myogenic function of ZNF37A may be related to its transcriptional effect on IL13RA1-the expression of which was also altered in our original transcriptomic analysis (5)-because it is a subunit for the receptor to the myoblast recruitment factor interleukin 13 (IL13).
RESULTS

ZNF37A expression is specifically altered in cells with DM1 mutation
In our original transcriptomic analysis of cells differentiated from stem cell lines derived from embryos carrying a DM1 gene (data available at GEO Data Bank; accession number GSE7214, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?a cc=GSE7214), ZNF37A was found highly downregulated in human embryonic stem cells (hESCs), hESCs-derived mesenchymal stem cells (MSCs) and hESCs-derived neural stem cells (NSCs) (5) . As previously shown, hES-derived MSCs are characterized by expression, at near homogeneity, of CD29 (b1-integrin), CD44 (H-CAM), CD73, CD105 and CD166, and are able to differentiate along osteogenic and adipogenic lineages when grown in appropriate conditions (10) . The two DM1 hESCs, VUB03_DM and VUB24_DM, carry 1000 and 3000 CTG triplet repeats, respectively, and their differentiation into NSCs and MSCs does not affect the size of the CTG triplet repeats (5) . ZNF37A gene encodes a zinc-finger protein that exhibits all the characteristics of the Krab-containing zincfinger protein family. This gene belongs to a cluster of genes encoding members of that family, which is located in the pericentromeric region of the chromosome 10p11.2-10q11.2 (Fig. 1A) . Specific down expression of ZNF37A was confirmed by quantitative reverse transcription-PCR ( Fig. 1B ; Supplementary Material, Fig. S1 ) and in situ hybridization (Supplementary Material, Fig. S1B) . At the protein level, western blot and immunofluorescence analysis (Fig. 1D -F ) also showed that ZNF37A expression was decreased in DM1 hES-derived MSCs, whereas the protein could be easily detected in the nucleus of control wild-type cells. Similarly, a strong gene expression defect was also observed both in skeletal muscle cell and brain tissue samples from DM1 patients (Fig. 1G -F) . DM1 affects ZNF37A expression by means of CUGBP1 control of its mRNA stability Molecular mechanisms linking this defect with DM1 were explored by analyzing the hypothesis that the stability of ZNF37A mRNA was compromised in diseased cells. Indeed, measurement of the stability of transcripts following inhibition of the transcription with Actinomycin D indicated a specific instability of ZNF37A mRNA in DM1 hES-derived MSCs as compared to control cells, whereas no effect of the treatment was observed on ZNF33A and ZNF37B, two other genes of the same family that belong to the same chromosomal cluster (Figs 1A and 2A; Supplementary Material, Fig. S2A ).
A part of the 5 ′ UTR region of the ZNF37A mRNA contains several UG-rich motifs (Fig. 2B) ; similar motifs have been shown to be CUGBP1-binding sites (11) . This observation, together with the fact that CUGBP1 function is known to be aberrant in DM1, suggested a link between CUGBP1 and the ZNF37A mRNA instability. To test this hypothesis, a luciferase reporter plasmid was used in which this part of the 5 ′ UTR_ZNF37A had been cloned upstream of the luciferase gene under a CMV promoter (Fig. 2B ). Transient transfection of this construct in DM1 hES-derived MSCs resulted in a statistically significant decrease in luciferase expression as compared with control cells, whereas no difference was observed in transfection efficiency ( Fig. 2C; Supplementary Material, Fig. S2B ). Similar results were obtained in wild-type HEK 293 cells after co-transfection of the luciferase construct together with a plasmid expressing a DMPK minigene that contains an abnormally long stretch of 960 interrupted CUG repeats ( Fig. 2F ; Supplementary Material, Fig. S2C and D) (12) . The overexpression of CUGBP1 resulted in a similar reduction in luciferase expression, whereas the overexpression of MBNL1, another RNAbinding protein known to be affected in DM1, had no effect (Fig. 2F) . Whether CUGBP1 controlled the expression of ZNF37A by means of direct binding to RNA was determined using gel shift retardation assays. Thus, four different RNA fragments derived from the ZNF37A 5 ′ UTR were incubated with increasing amounts of recombinant CUGBP1 protein and the complexes were separated on a native polyacrylamide gel. CUGBP1 seemed to bind predominantly two different fragments (fragment 2 and fragment 4) of the 5 ′ UTR of ZNF37A ( Fig. 2D  and E) . The deletion of a region that contained CUGBP1-binding motifs in 5 ′ UTR_ZNF37A-luc construct (Delta A) resulted in a loss of effect of the DMPK minigene containing 960 CUG repeats as well as a loss of effect of CUGBP1. In contrast, the deletion of a region (Delta B) that does not contain putative CUGBP1-binding motifs did not affect the response of the 5 ′ UTR_ZNF37A-luc construct (Fig. 2F) . However, we cannot exclude, as it was recently suggested by different studies, that the RNA secondary structure may facilitate CUGBP1 binding by bringing into close proximity UGU sequences dispersed throughout the region (13, 14) . Thus, the identification of CUGBP1-binding sites might not be clearly as simple as pinpointing extensive UG-rich regions and further investigation will be necessary to enable accurate prediction of CUGBP1 targets. An alternative hypothesis for explaining the defect in ZNF37A expression was the presence of a putative alternative splice site in the 5 ′ UTR of ZNF37A, which may alter the stability of the ZNF37A transcript. To test this hypothesis, the construct was inserted upstream of the luciferase gene in an inverse position. Similar results were obtained regardless of the sense of the insertion (Supplementary Material, Fig. S2E ), thus ruling out the presence of an alternative splicing defect. This was further confirmed by the lack of effect of either CUGBP1 overexpression or the introduction of the construct carrying 960 CUG repeats on the alternative splicing of this region (Supplementary Material, Fig. S2F ). Altogether, these results suggest that DM1-specific ZNF37A down expression is linked to a CUGBP1-dependent mRNA destabilization mechanism.
ZNF37A down expression results in altered myogenesis that may involve the IL13 receptor a1 subunit
In an attempt to identify a functional link between the defect in ZNF37A expression and DM1, the former's role was explored. Judging from its nuclear subcellular localization ( Fig. 1D-E) and its sequence analysis, ZNF37A exhibits all the characteristics of Krab-containing zinc-finger proteins, which generally function as transcriptional repressors (15) . Accordingly, co-immunoprecipitation on the nuclear fraction of control hES-derived MSCs demonstrated a direct interaction between ZNF37A and Kap1, a common co-repressor of Krab-domain transcription factors (Supplementary Material, Fig. S3A ).
It was, therefore, postulated that ZNF37A down expression in DM1 cells might induce upregulation of its target genes in the same cells. Among the seven candidates found to be upregulated in our original study (5) , the a1 chain of the receptor to IL13 (IL13RA1) was especially appealing because its expression level was inversely correlated to that of ZNF37A not only in mutant hES cells and derivatives at all stages and types of differentiation but also in DM1 patients' myotubes samples ( Fig. 3A  and B; Supplementary Material, Fig. S3B ). The knockdown of ZNF37A expression by specific siRNA in wild-type H9 hESderived MSCs led to an increased expression of IL13RA1, confirming that ZNF37A negatively controls the expression of IL13RA1 (Fig. 3C) . As a control of the specificity of those effects, ZNF37A-directed siRNA had no effect on the expression level of eIF2S3, another gene upregulated in the mutant cells (Supplementary Material, Fig. S3C ). Chromatin immunoprecipitation directed against ZNF37A, followed by a quantitative PCR analysis with primers covering the entire IL13RA1 promoter, revealed a potential-binding site for ZNF37A that did not exist in the promoter region of eIF2S3 ( Fig. 3D ; Supplementary Material, Fig. S3D and E) . IL13RA1 is part of the common receptor for IL4 and IL13, two cytokines that participate to the recruitment of myoblasts and promote myogenic fusion (16, 17) . Function of ZNF37A was, therefore, evaluated on muscle cell differentiation. Control human primary myoblasts transfected either with one of two different siRNA against ZNF37A (Supplementary Material, Fig. S4A and B) or with control siRNA were differentiated into myotubes. Down expression of ZNF37A did not affect the generation of myotubes, as determined by the detection of myosin heavy chain (MF20 positive cells). In contrast, a defect in the number of nuclei per MF20 positive cells was observed, similar to that observed in human primary myoblasts derived from DM1 patients ( Fig. 4; Supplementary Material, Fig. S4C ). These results suggested that the down expression of ZNF37A might not affect the differentiation process, but instead plays a role in the myoblast fusion at a specific stage of myogenesis Figure 4 . Down expression of ZNF37A affects myogenic differentiation in vitro. Detection of myogenic markers by immunostaining 6 days after specific ZNF37A siRNA transient transfection in control myoblasts. Desmin detects muscle cells (green); MF20 detects differentiated myoblasts (red) and Dapi (blue) labels nuclei. Scale bar ¼ 50 mm. Quantification of the myogenic impairment is measured by the number of nuclei per MF20 positive cells. A total of 1000 MF20 was counted for each condition. Data are presented as mean + SEM (n ¼ 3) and were analyzed with a 'Bonferroni's multiple comparison test' (one-way ANOVA), ns: no statistical difference, * P , 0.05, * * P , 0.001.
after the initial formation of a myotube. No statistical difference was observed between DM1 myotubes and siZNF37A-treated cells, suggesting that the down expression of ZNF37A led to a similar phenotype to that observed in DM1 cells. This action window of ZNF37A on myogenesis could be correlated with the one of the cytokines IL13 and IL4, which reinforced the hypothesis of a mechanistic action of ZNF37A via IL13RA1. To validate this point, the effect of IL4/IL13 treatment on myogenesis was compared between DM1 cell cultures and wild-type cells treated to knock down the expression of ZNF37A. In the controls, IL4/IL13 treatment increased the ability of wild-type myoblasts to mature into multinucleated myotubes. In sharp contrast, no similar effect of the treatment was observed in either DM1 myoblasts or wild-type myotubes after knocking down the expression of ZNF37A using specific siRNAs (Fig. 5) which thus establishes the contribution of ZNF37A to the myogenic effect of IL4/IL13.
DISCUSSION
The main finding of this study is the demonstration that, in cells carrying the DM1 mutation, the observed decreased expression of the transcription factor ZNF37A bears functional consequences for myogenesis. These results from a defect in IL4/ IL13 signaling that may involve alteration of expression of the IL13RA1 receptor subunit. At the molecular level, the DM1 mutation most likely affects ZNF37A expression via a mechanism that involves abnormal control of its mRNA stability by the RNA-binding Protein CUGBP1.
The currently accepted pathological model of DM1 holds that manifestations result from alteration of two main proteins involved in pre-mRNA splicing, namely MBNL1, which is sequestered in the nucleus due to its association with the repeatcontaining mRNA (18) , and CUGBP1, which is overexpressed and hyperphosphorylated in the nucleus of DM1 cells (19) . Recent studies have shown that not all DM1 pathological mechanisms can be explained by altered alternative RNA splicing. By characterizing affected genes in a DM1 transgenic mouse model expressing 250 CUG repeats in 3 ′ UTR of the skeletal actin mRNA, Osborne et al. have shown that RNA containing (CUG) expansions interfere at both transcriptional and posttranscriptional levels (20) . Similarly, the misexpression of CUGBP1 contributes to the alteration in muscle development in DM1 by affecting the translation efficiency of p21 via binding to a GC-rich sequence located within the 5 ′ region of p21 mRNA (21, 22) . CUGBP1 also acts as an mRNA stabilizing factor associated with short-lived mRNAs (23) and contributes to muscle wasting in DM1 by affecting the decay of TNF mRNA in DM1 muscle cells (13) . Collectively, these observations and our results support the conclusion that the function of CUGBP1 on the turnover of mRNA has a more extensive impact on DM1 pathogenesis than previously thought.
The involvement of a zinc-finger transcription factor in DM1 requires a comparison with DM2, a myotonic dystrophy disorder characterized by CCUG mRNA expansions (24) in ZNF9, another member of zinc-finger transcription family. The clinical analogies between DM1 and DM2 have led to the suggestion of a common trans-acting mechanism with depletion of similar transcription factors (25) . The observation that haploinsufficiency for Znf9 is associated with multiorgan abnormalities resembling myotonic dystrophy reinforces this notion (26, 27) . It is therefore tempting to postulate that a common requirement for transcription factors in tissues expressing the mutant DMPK may be partially responsible for some of the multisystemic symptomatology of DM1 (e.g. myotonia, myopathy, insulin resistance, cognitive impairment). To address this issue, it would be interesting to undertake a systematic search for target genes impacted by the loss of ZNF37A expression in DM1.
The DM1 mutation interferes with myogenesis, but the exact mechanism of this phenomenon has not yet been clarified (3, 28) . IL13 and IL4 can be considered as interesting candidates because of their role in myoblast fusion during muscle development and regeneration (16, 17, 29) . It was, therefore, particularly interesting to observe that ZNF37A, which interferes with myogenesis when defective, was found to modulate the expression of IL13RA1. This gene encodes a receptor subunit that combines with IL4RA to form the heterodimeric receptor for the IL4 and IL13 cytokines (30) . IL13RA1 expression also increases soon after muscle injury, suggesting that this receptor plays a role in muscle regeneration (31). Increased expression of IL13RA1 in DM1 cells as a consequence of a loss of expression of ZNF37A may, therefore, bear some significance for myogenesis and/or regeneration (32 -35) . Consistent with this, DM1 differentiated myoblasts did not respond to IL13/IL4 treatment in an in vitro model of myogenic fusion as control cells did.
However, it has been shown that IL-4 and IL-13 could share the redundant ability to recruit mononucleated cells for fusion but not toward the same cell populations: IL-4 being responsible for the 'normal' myoblast fusion into nascent myotubes during myogenic differentiation, and IL-13 for additional recruitment of reserve cells during skeletal muscle hypertrophy that may prevent the loss of muscle mass (16, 17, 29) . Therefore, it will be interesting to determine the exact function of IL4 and IL13 in the DM1 phenotype observed.
Most previous analyses of DM1 pathological mechanisms attempted to associate clinical symptoms and alteration of the processing of specific candidate proteins. These hypothesis-driven studies unavoidably ignored genes that could not be directly linked to identified symptoms. We have begun to provide a complementary list of genes that appear to be specifically modified by the presence of DM1 mutation by combining the use of DM1-mutant hES cells-derived progenies and global gene expression profiling. Although validation of the exact mechanisms by which DM1 affects these genes has yet to be provided and the effect of their abnormal expression on cell metabolism still has to be defined, these genes are candidates for new pathological pathways associated with DM1. We previously demonstrated that this approach could be used to identify new physiopathological mechanisms implicated in the neuritogenesis and synaptogenesis of motoneurons (5) . The present study confirms the usefulness of such a resource-driven approach based on gene-carrying pluripotent stem cell lines. This study also highlights the potential offered by the use of disease-specific human pluripotent stem cells to decipher physiopathological mechanisms in a large spectrum of cell types, and therefore points out the added value of this approach for multisystemic diseases.
MATERIALS AND METHODS
Cell culture
Mutants hES cell line (VUB03_DM, XX, passages p70 -p90; and VUB24_DM; XX, passages p30 -40, derived in AZ-VUB) and wild-type human ES cells (H9, XX, passages 40-60; WiCell Research Institute; VUB01, XY, passages p80 -90) were maintained as previously described (36) .
Control and DM1 myoblasts were cultured in D-MEM/F-12 medium (Invitrogen) supplemented with 20% SVF (Eurobio) and 0.1% of penicillin -streptomycin (Gibco). For differentiation, cells were transferred to 2% SVF D-MEM/F-12 medium for 6 days. Neural and mesodermal differentiation were achieved using established methods (5, 10, 37) . Briefly, mesodermal stem cells were obtained after plating hES cells onto gelatin-coated plates with medium containing 20% of fetal bovine serum for 21 days. The purity of the mesenchymal cultures was validated by FACS analysis for different markers such as CD73 (5, 10) . hES cell lines were differentiated into neural precursor cells by using a co-culture with MS5 stromal cells. After 2 -3 weeks of culture, neural precursor cells appear as neural rosette structures. Neural precursor cells were FACS-sorted on the basis of NCAM expression.
Control and DM1 myoblasts with .2000 repeats (kindly provided by Dr. D. Furling) were isolated from quadriceps muscles biopsies obtained from the Myobank in accordance with the French legislation on ethical rules. The fetal brain RNA (kindly provided by Dr. G. Gourdon, Inserm U781) was obtained from fetuses aged from 12 to 25 amenorrhea weeks. DM1 samples were affected to different degrees (97 -1500 CTG repeats). The adult brain RNA samples (kindly provided by Dr. M. Gomez-Pereira, Inserm U781) were obtained from cortical biopsies of adult forms of DM1 and contained different sizes of CTG expansion ranging from 200 to 1000.
Real-time reverse transcriptase polymerase chain reaction and Agilent DNA chips analysis
Total RNA from cells was isolated using the 'RNeasy Mini Protocol' (Qiagen). cDNA was synthesized by using SuperScript III (Invitrogen). Quantitative real-time reverse transcriptase -polymerase chain reaction (RT -PCR) was optimized to determine the linear amplification range by using a Chromo4 Real-Time System (Bio-Rad) with Syber Green PCR Master Mix (Applied Biosystems). For Agilent Chips analysis, PCR products were quantified using the DNA 1000 Kit for the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, France) according to the manufacturer's protocol. Primers are listed in Supplementary Material, Table S1 .
Actinomycin treatment
hES-derived MSCs control (H9) and DM1 (VUB03_DM) were plated at 5 × 10 4 cells per well (70 -80% confluency in 24-well plate) and were treated with 5 mg/ml of Actinomycin (Sigma) during 30, 90 and 180 min. Total RNA from cells was isolated as described above and quantitative real-time RT -PCR was performed.
Luciferase assays
5
′ UTR_ZNF37A-luc plasmid was obtained by PCR using specific primers amplifying DNA intron 1 to intron 3. The PCR product was purified and cloned in pGL4.82 (Promega) modified with CMV promoter. HEK293 cells were plated at 2.5 × 10 4 cells/cm 2 in 96-well plate in Alpha MEM medium supplemented with 10% SVF (Hyclone) and 1% Glutamax, 1% nonessential amino acids and 1% penicillin -streptomycin (Gibco). Twenty-four hours after plating, the cells were co-transfected with 100 ng of the 5 ′ UTR_ZNF37A-luc, 100 ng of Delta A or 100 ng of Delta B, 250 ng of the pGFP (Lonza) and 250 ng of pCTG (960 interrupted repeats) or 100 ng of pCUGBP1 or 100 ng of pMBNL1 plasmids in OptiMEM medium using Lipofectamine TM LTX PlusReagent (Invitrogen). Forty-eight hours after transfection, the luciferase substrate was applied using Enduren TM Live Cell Substrate (Promega). Luminescence reading was performed using Analyst GT (Molecular Devices). For cell normalization, CellTiterGlo w Luminescent Cell Viability Assay (Promega) was used.
Transient siRNA knockdown
The sequences targeted by chemically synthesized siRNAs in transient knockdown experiments were as follows: Hs_ZNF37A_7 HP siRNA (Qiagen), Hs_ZNF37A_9 HP siRNA (Qiagen) and Silencer w Negative Control siRNA (Ambion, Applied Biosystems). MSCs were plated at 5 × 10 4 cells per well (70 -80% confluency in 24-well plate) and were transfected the following day with 10-40 nmol siRNA in OptiMEM medium by using LipoRNAiMax (Invitrogen).
Myoblasts were plated at 8 × 10 4 cells per well in 12-well plate. The following day, they were transfected with 10 pmol siRNA in OptiMEM medium by using Lipofectamine 2000 (Invitrogen) in differentiated medium. Forty-eight hours after transfection, RNA was isolated and quantitative real-time RT-PCR was performed as described above to check the specific ZNF37A down expression.
Immunocytochemistry
Cultured cells were fixed in 4% paraformaldehyde in PBS and were incubated with the monoclonal antibody against ZNF37A (R&D System, 1/500) at 48C for 12 h. Appropriate FITC-labeled secondary antibodies (Jackson ImmunoResearch) were used. For myogenic characterization, the cells were fixed in 4% paraformaldehyde in PBS and were incubated with the monoclonal antibody MF20 (DSHB, 1/200) and Desmin (1/25 R&D System) at RT for 2 h. Then the cells were incubated with Monoclonal Cy3 and Cy2 and Dapi at RT for 2 h. Images were captured using a Zeiss fluorescent microscope.
Chromatin immunoprecipitation
Chromatin immunoprecipitation analyses were carried out as described (38, 39) . Briefly, genomic DNA and proteins were cross-linked by formaldehyde (1% final) and quenched with glycine 1 M. Cells were sonicated eight times to generate 100 -1000 bp DNA fragments. Before addition of antibody, 100 ml of lysate was saved as the input sample. Either anti-acetyl H3, CT, pan A3S (Millipore, 5 mg), monoclonal anti-ZNF37A (R&D System, 5 mg), monoclonal anti-Isl2 or MAP2 (DSBH Bank, 5 mg) was incubated with lysates overnight at 48C. Immune complexes were purified using Dynead beads (Invitrogen) and eluted at 1008C for 10 min. DNA was extracted using purification columns (Nalgene) and quantitative PCR was carried out and analyzed as described in (40) using the primers described in Supplementary Material, Table S1 .
In vitro transcription and gel shift assay
RNAs for gel shift experiments were transcribed using a cap analog and SP6 polymerase in the presence of a-32P- [UTP] . RNA mobility shift assays were performed with increasing concentrations of recombinant CUGBP1 as described previously (41) . Recombinant proteins were diluted in buffer D containing 0.5 mg/ml bovine serum albumin. The reaction was incubated for 15 min at 308C, and the protein complexes were resolved by electrophoresis on a 6% non-denaturing polyacrylamide gel (39/1), 0.5× TBE. RNA bands were quantified using a PhosphorImager (Molecular Dynamics)
Co-immunoprecipitation and western blot analysis
Co-immunoprecipitation and western blot analyses were performed as previously described (42) . Briefly, proteins were extracted with RIPA buffer (Invitrogen) and were quantified using a BCA protein assay kit (Pierce). For co-immunoprecipitation, 100 mg of proteins were incubated overnight at 48C with 10 mg of antibodies against either ZNF37A (Abnova) or Kap1 (Abnova). Precipitation were performed with Dynabeads w Protein A (LifeTech w ) according to manufacturer's protocol. For western blot, 15 mg of proteins were loaded on NuPAGE 4-12% Bis-Tris Gels (Invitrogen) and transferred onto a nitrocellulose membrane (Invitrogen). Primary antibodies for ZNF37A (1/500, Abnova), H3 PAN (1/1000, Millipore), b-Actin (1/100 000, Sigma), MBNL1 (1/7000, kindly provided by Dr. Furling) and CUGBP1 (1/1000, Santa Cruz Biotechnology) have been used. Western blot proteins were determined by using Novexw ECL Kit (LifeTech). For ZNF37A blots, nuclear and cytoplasm proteins were extracted using NE-PER Extraction Kit (Pierce).
IL13/IL4 treatment
Myoblasts were plated at 8 × 10 4 cells per well in 12-well plate. The following day, they were treated with 50 ng/ml of IL13 and IL4 (R&D System) in differentiation medium. The medium was changed after 4 days, and the cells were fixed on day 6.
Statistical analysis
The data were processed using Prism5.0c. Values are reported as means + SEM. Comparisons between two groups were made with Student's t-test (ANOVA). For comparisons of more than two groups, 'Bonferroni's multiple comparison test' (one-way ANOVA) was performed.
